drugset / Trial / NCT00002244

A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients With Late-Stage HIV Disease

NCT00002244

Phase 3 Completed 240 enrolled Oxo Chemie GmbH
Double-blindTreatment

Summary

The purpose of this study is to see if it is safe and effective to give WF10 to adults with late-stage HIV disease. WF10 is suspected to help the immune system fight infection and slow HIV disease progression.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject WF10 Other / unclassified Intravenous